Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment: core label-supported statements (indication, statin class, mechanism, CYP3A4 involvement, grapefruit interaction) are present, but multiple avocado-related claims are not supported by the FDA label, and one statement about CYP3A4 inhibition would contradict known labeling.
Category Scores
Accurate Statements
Lipitor is a prescription medication used to lower cholesterol levels and reduce cardiovascular risk.
Indication (1.1, 1.2)
Lipitor belongs to the statin class of lipid-lowering agents.
12.1
Statins inhibit HMG-CoA reductase, reducing cholesterol synthesis in the liver.
12.1
CYP3A4 is involved in atorvastatin metabolism.
12.3
Grapefruit juice can interact with Lipitor and increase atorvastatin exposure.
7.2
Unsupported Statements
There is no concrete evidence to suggest that avocados directly interact with Lipitor.
Not addressed in labeling; avocado interactions are not described.
Some studies have raised concerns about the potential effects of combining these two.
Label contains no avocado–Lipitor interaction data.
A diet rich in avocados may increase the levels of certain enzymes in the body.
No labeling evidence linking avocado intake to enzyme level changes affecting atorvastatin.
The increased enzyme levels could potentially affect the metabolism of statins like Lipitor.
Label does not describe avocado-related enzyme effects on statin metabolism.
Avocado consumption could increase the levels of enzymes that inhibit CYP3A4.
Label does not indicate avocado-induced CYP3A4 inhibition.
Reduced levels of atorvastatin could potentially reduce Lipitor's effectiveness.
Label does not describe reduced exposure leading to decreased efficacy due to avocado.
DrugPatentWatch.com states there is no known interaction between Lipitor and avocado.
Not part of FDA labeling; external site.
While there is some evidence to suggest that avocado consumption may affect the metabolism of statins, the impact is likely to be minimal.
Not addressed in labeling.
The impact of avocado consumption on statin metabolism is likely to be minimal.
Not addressed in labeling.
Eating avocados while taking Lipitor is possible, but you should consult a healthcare professional before making significant dietary changes.
Not specifically addressed in label.
Avocado consumption reducing the effectiveness of Lipitor is unlikely, but the impact is still unclear and may depend on individual factors.
Not supported by labeling.
Grapefruit and pomegranate may interact with Lipitor, but the impact is still unclear.
Grapefruit is addressed; pomegranate is not described in labeling.
Do not stop taking Lipitor without consulting with a healthcare professional.
Not a direct labeling statement; general medical guidance exists but phrasing not from label.
Contradictions
Low
AI Statement
Increased enzymes that inhibit CYP3A4 could lead to reduced levels of atorvastatin in the body.
Label Reference
7.1, 12.3
Important Omissions
Pregnancy risk and teratogenicity information
Importance:
High
Boxed warnings and risk of myopathy/rhabdomyolysis with statins
Importance:
High
Contraindications (e.g., active liver disease) and safety in specific populations
Importance:
High
Pediatric safety and dosing
Importance:
High
Storage and handling specifics
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most avocado-related claims are unsupported; known pharmacokinetic interactions (CYP3A4, grapefruit) are limited and described in label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Avocado-related claims are not supported by the FDA label; grapefruit interaction is established. Avoid presenting avocado-specific metabolism claims as facts.
Suggested Improvement
Limit statements to label-supported interactions; explicitly acknowledge grapefruit interaction per labeling; remove avocado-specific interaction claims; consider including a general caution to discuss dietary changes with a clinician.